The University of Chicago Header Logo

Connection

Anthony T. Reder to Male

Back to Details
This is a "connection" page, showing publications Anthony T. Reder has written about Male.
Anthony T. Reder
Connection Strength
0.548
Male
  1. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
    View in: PubMed
    Score: 0.041
  2. Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17.
    View in: PubMed
    Score: 0.039
  3. Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
    View in: PubMed
    Score: 0.037
  4. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient. 2016 Apr; 9(2):171-80.
    View in: PubMed
    Score: 0.029
  5. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
    View in: PubMed
    Score: 0.024
  6. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct; 69(10):1303-9.
    View in: PubMed
    Score: 0.023
  7. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
    View in: PubMed
    Score: 0.019
  8. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology. 2009 Mar 24; 72(12):1100-1.
    View in: PubMed
    Score: 0.018
  9. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
    View in: PubMed
    Score: 0.017
  10. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
    View in: PubMed
    Score: 0.017
  11. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008 May; 28(5):317-31.
    View in: PubMed
    Score: 0.017
  12. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci. 2004 May 01; 9:1547-55.
    View in: PubMed
    Score: 0.013
  13. Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult Scler. 2003 Mar; 9(2):160-70.
    View in: PubMed
    Score: 0.012
  14. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
    View in: PubMed
    Score: 0.011
  15. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
    View in: PubMed
    Score: 0.009
  16. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
    View in: PubMed
    Score: 0.008
  17. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol. 1998 Jan; 81(1-2):109-15.
    View in: PubMed
    Score: 0.008
  18. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
    View in: PubMed
    Score: 0.008
  19. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep; 9:158-62.
    View in: PubMed
    Score: 0.007
  20. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996 Apr; 1(5):262-9.
    View in: PubMed
    Score: 0.007
  21. Clinical and genetic studies of fatal familial insomnia. Neurology. 1995 Jun; 45(6):1068-75.
    View in: PubMed
    Score: 0.007
  22. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.007
  23. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
    View in: PubMed
    Score: 0.007
  24. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep; 3(5):629-38.
    View in: PubMed
    Score: 0.006
  25. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
    View in: PubMed
    Score: 0.006
  26. Adrenal size is increased in multiple sclerosis. Arch Neurol. 1994 Feb; 51(2):151-4.
    View in: PubMed
    Score: 0.006
  27. Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav. 2014 Feb; 31:77-84.
    View in: PubMed
    Score: 0.006
  28. Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci. 1993 Jul; 117(1-2):192-6.
    View in: PubMed
    Score: 0.006
  29. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
    View in: PubMed
    Score: 0.006
  30. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013 Jan; 131(1):103-7.
    View in: PubMed
    Score: 0.006
  31. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992 Dec 15; 114(6):731-6.
    View in: PubMed
    Score: 0.006
  32. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
    View in: PubMed
    Score: 0.006
  33. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
    View in: PubMed
    Score: 0.006
  34. Interferon-beta treatment does not elevate cortisol in multiple sclerosis. J Interferon Res. 1992 Jun; 12(3):195-8.
    View in: PubMed
    Score: 0.006
  35. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012 Jun 05; 78(23):1860-7.
    View in: PubMed
    Score: 0.005
  36. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
    View in: PubMed
    Score: 0.005
  37. Severe tetanus in immunized patients with high anti-tetanus titers. Neurology. 1992 Apr; 42(4):761-4.
    View in: PubMed
    Score: 0.005
  38. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
    View in: PubMed
    Score: 0.005
  39. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.005
  40. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
    View in: PubMed
    Score: 0.005
  41. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
    View in: PubMed
    Score: 0.005
  42. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
    View in: PubMed
    Score: 0.005
  43. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
    View in: PubMed
    Score: 0.005
  44. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
    View in: PubMed
    Score: 0.005
  45. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.005
  46. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
    View in: PubMed
    Score: 0.005
  47. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 Mar; 195(1-2):116-20.
    View in: PubMed
    Score: 0.004
  48. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology. 1987 May; 37(5):849-53.
    View in: PubMed
    Score: 0.004
  49. Molecular analysis of the CD8 gene in multiple sclerosis. J Neuroimmunol. 1987 Mar; 14(2):183-7.
    View in: PubMed
    Score: 0.004
  50. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
    View in: PubMed
    Score: 0.003
  51. Clinical spectrum of multiple sclerosis. Neurol Clin. 1983 Aug; 1(3):573-99.
    View in: PubMed
    Score: 0.003
  52. B-cell differentiation in multiple sclerosis and the effect of intravenous ACTH. Neurology. 1983 Apr; 33(4):442-6.
    View in: PubMed
    Score: 0.003
  53. Epilepsy evoked by eating: the role of peripheral input. Neurology. 1982 Sep; 32(9):1065-9.
    View in: PubMed
    Score: 0.003
  54. Neurologic Munchausen's redux. Neurology. 1982 Feb; 32(2):216.
    View in: PubMed
    Score: 0.003
  55. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
    View in: PubMed
    Score: 0.002
  56. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.002
  57. The mast cells of the multiple sclerosis brain. J Neuroimmunol. 1996 Nov; 70(2):131-8.
    View in: PubMed
    Score: 0.002
  58. Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol. 1993 Mar; 43(1-2):1-7.
    View in: PubMed
    Score: 0.001
  59. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.001
  60. Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct; 80(5):339-46.
    View in: PubMed
    Score: 0.001
  61. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.001
  62. Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test. Am J Psychiatry. 1985 Nov; 142(11):1278-84.
    View in: PubMed
    Score: 0.001
  63. Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. Am J Psychiatry. 1984 Nov; 141(11):1365-70.
    View in: PubMed
    Score: 0.001
  64. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.